Cytokinetics

Cardiovascular Account Specialist - U.S. Sales, Savannah/Columbus/Macon, GA

Remote

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Position Overview

  • Location Type: Remote
  • Employment Type: Full-time
  • Salary: Not specified

As a Cardiovascular Account Specialist, you will introduce Cytokinetics in your dedicated territory and launch its first commercial product, a novel cardiac myosin inhibitor for Hypertrophic Cardiomyopathy (HCM). You will be responsible for driving performance by working synergistically with internal stakeholders and external customers. Success will require you to identify and develop business relationships with strategic IDNs and Hospitals, cardiology clinics, and specialty pharmacies while establishing yourself as a resource within these care settings. You will need to demonstrate strategic thinking, passion for our core values, and a proactive approach in supporting the Company’s Mission to help address patients’ unmet needs.

Requirements

  • Education: Bachelor’s Degree required
  • Experience: 5+ years of experience in biotech/pharma sales required
  • Territory Ownership: Experience as a rep with sole ownership of the territory is highly preferred
  • Preferred Experience:
    • Cardiology, rare disease, or specialty product experience
    • Specialty product launch experience
    • Experience with patient service hubs and specialty pharmacy distribution

Responsibilities

  • Deliver sales results and work autonomously.
  • Serve as the single point of accountability for the successful launch within your territory.
  • Develop territory-specific account plans, identifying and prioritizing opportunities to meet customer needs.
  • Coordinate the efforts of a local integrated field team (medical, payer, and patient navigation/support colleagues).
  • Be a subject matter expert and resource to customers, delivering clinically relevant disease and product information.
  • Communicate approved resources to HCPs for the benefit of HCM patients (marketing materials, payer information, formulary coverage, patient support services, and educational programs).

Company Information

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. Our passion is anchored in our four core values:

  • Patients are our North Star: Our actions and decisions are dedicated to benefiting patients and their caregivers.
  • Science is in our Soul: We are committed to scientific excellence, integrity, and critical thinking, free from external influences.
  • We > Me: Our strength lies in our unity and diversity.
  • Make it Happen: We navigate challenges with tenacity, resilience, and a forward-thinking mindset, always holding ourselves accountable for delivering impactful results.

Skills

Biotech
Pharma Sales
Cardiology
Rare Disease
Specialty Product Launch
Patient Service Hubs
Specialty Pharmacy Distribution
Territory Management
Account Planning
Customer Relationship Development
Clinical Disease and Product Knowledge

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

South San Francisco, CaliforniaHeadquarters
1998Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Risks

Increased competition could impact market share and profitability.
Potential delays in clinical trials could hinder drug commercialization.
Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
The company has a robust pipeline including omecamtiv mecarbil and aficamten.
Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.
Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI